MedTrace Logo

20 Week Bridging Study in Type II DM

NCT00563225 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2007-11-26

No results posted yet for this study

Summary

A multicenter, non-comparative, one arm, open, phase III study to evaluate the efficacy and safety of insulin glargine on subjects with Type 2 Diabetes Mellitus

Conditions

  • Diabetes Mellitus Type II

Interventions

DRUG

Insulin Glargine

Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)

Sponsors & Collaborators

Principal Investigators

  • Choe Seong Choon · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Completion
2004-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00563225 on ClinicalTrials.gov